A federal district court in Delaware construed disputed claims in Genzyme Corp. and Aventis Inc.'s action against Novartis Gene Therapies Inc. and Novartis Pharmaceuticals Corporation for infringement of patents that concern the making of recombinant gene therapy vectors. The court construed “A 5' AAV inverted terminal repeat sequence, a first heterologous nucleotide sequence, an internal AAV ITR sequence, a second heterologous nucleotide sequence, and a 3' AAV ITR sequence;" “recombinant AAV vector;" “rAAV vector genome” / “rAAV genome;" “along most or all of its length” / “along its length;" and other terms.